The anticipated size of the phakic intraocular lenses (PIOL) market in 2022 was US$ 377.1 million and is estimated to be US$ 412.9 million in 2023.
The surge in number of people who are myopic have found to be risen in recent years, as this refractive correction option has become increasingly significant. According to Future Market Insights, the phakic intraocular lenses (IOL) market is anticipated to expand at a CAGR of 8.1% between 2023 and 2033, totaling around US$ 897.4 million by 2033.
The global phakic intraocular lenses (PIOL) market reached US$ 344.4 million in 2021. Sales are projected to expand at a 9.5% CAGR over the assessment period, with the market valuation reaching US$ 819.5 million by 2032. Posterior chamber phakic IOL is leading the market. The segment accounted for about 68.0% of the total market share in 2021, and the trend is expected to continue over the forecast period.
Phakic intraocular lenses (PIOLs) are clear implantable lenses that are surgically inserted in the anterior chamber or the posterior chamber of the eye without removing the natural lens, allowing light to focus on the retina for better-uncorrected vision.
Phakic intraocular lenses have a high optical quality and might potentially improve visual acuity in myopic patients due to retinal magnification. PIOL implantation appeals to both patients and refractive surgeons since it is a reversible refractive technique that preserves accommodative function. Further, corneal thickness poses little bearing on correction, and hence, PIOLs offer fast visual recovery times, and steady refraction after implantation.
| Attribute | Details |
|---|---|
| Projected Forecast Value (2022) | US$ 377.1 million |
| Projected Forecast Value (2023) | US$ 412.9 million |
| Projected Forecast Value (2033) | US$ 897.4 million |
| Growth rate | 8.1% CAGR |
| Forecast period | 2023 to 2033 |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global phakic intraocular lenses market expanded at a CAGR of 10.3% between 2018 and 2022. Growth forecasts remain optimistic, with the market predicted to exhibit a CAGR of 8.1% between 2023 and 2033.
The phakic intraocular lenses market represented around 7.0% of the overall US$ 4.9 billion global intraocular lenses market in 2021.
Phakic intraocular lenses are a popular surgical option for correcting myopia. Anterior chamber iris-fixated, anterior chamber angle-supported, and posterior chamber phakic intraocular lenses are the three types of lenses available. Although phakic intraocular lenses have high efficacy, they have undergone numerous improvements over the years to improve their safety profile and reduce lens-related problems such as cataract formation, endothelial cell death, and corneal decompensation.
For long-term management of stable myopia, lens surgery for refractive purposes (refractive lens exchange [RLE]), laser refractive surgery, and phakic intraocular lens (pIOL) implantation are available currently. Further, refractive surgery with pIOL implantation is a reversible technique, whereas laser refractive surgery and refractive lens exchange are permanent procedures.
Phakic IOL surgery has been proven to enhance vision, promote patient satisfaction, and reduce the risk of corneal ectasia. Phakic IOLs outperform LASIK and photorefractive keratectomy in terms of best spectacle-corrected visual acuity (BSCVA), refractive predictability and stability, and patient satisfaction. Complications of corneal ectasia associated with excimer laser surgery and refractive lens exchange are eliminated through the use of PIOLS. The phakic intraocular lenses (IOL) market is being driven by factors such as:
Revolutionization of Refractive Surgery in the Case of Phakic Intraocular Lenses
Phakic intraocular lenses have revolutionized refractive surgery and continue to be a great alternative for individuals who are not ideal candidates for laser vision correction. Since no ultrasonic energy is communicated to the ocular tissues, visual recovery is swift and intraocular inflammation is limited with phakic IOL implantation compared to cataract extraction with phacoemulsification.
There is no regression impact with phakic IOLs, unlike excimer laser operations, because corneal healing is not required. For patients with residual spherical or astigmatic refractive error after phakic IOL implantation, an excimer laser enhancement approach may be required.
For stable keratoconus, PIOL implantation is a viable refractive surgical approach. After cataract surgery, PIOL has also been demonstrated to be a useful and reliable choice for improving postoperative refractive performance and lowering spectacle dependence.
Presbyopia treatment with a multifocal implantable phakic refractive IOL, such as the presbyopia implantable phakic contact lens (PIOL), is a recent breakthrough. This novel PC-PIOL is meant to correct presbyopia, myopia, hyperopia, and astigmatism in those aged 40 to 55 who do not have cataracts. With good unassisted eyesight, the PC-PIOL has the distinction of being reversible.
Owing to these advancements within the field of intraocular lenses and technological advancements in the ocular manifestation of vision correction, the global market for phakic intraocular lenses is set to gain traction over the forecast period.
Principal Consultant
Lack of Reimbursements for Implantation Procedures
Lack of reimbursements for implantation procedures has proven to be a key roadblock to the overall phakic intraocular lens market. While secondary implant procedures are sometimes covered by Medicare, surgeries conducted primarily for refractive purposes are not.
For patients with presbyopia and high hyperopia, alternative treatments such as refractive lens exchange may be a superior preference to phakic IOL refractive surgery. Because of the high costs of phakic intraocular lenses and their implantation procedures, as well as the lack of standardized reimbursement schemes, the market faces a challenge in terms of patient uptake.
While lens replacement surgery is technically not approved by the FDA, some eye doctors will conduct it off-label in specific circumstances. This is legal and is sometimes the most effective method to rectify distinct vision abnormalities. These factors are expected to limit sales in the market over the forecast period.
Rising Preference for Phakic Lens Implant Surgery is Estimated to Augment Growth
The United States of America dominated North America’s phakic intraocular lenses market, accounting for about 24.3% of the total market share whereas North America holds a value share of 28.7%. Rising awareness regarding personalized medicine as well as targeted disease therapy is expected to boost the market in the forthcoming years.
With high technological demand arising from growing awareness, as well as large volumes of ophthalmic patients using spectacles for corrective vision enhancement, the adoption of phakic intraocular lenses within the country is set to increase over the forecast period.
Growing Popularity of Phakic Implants Will Spur Demand
Sales in China are expected to increase at an 11.80% CAGR over the forecast period. According to the IAPB's Word Report on Vision issued in 2019, the cataract patient population between the age group of 45 to 89 years is expected to reach 132 million by 2020. This also means that intraocular lenses are in high demand in China.
The cataract surgery market has expanded from 2.4 billion Yuan in 2005 to 25.5 Billion Yuan in 2018, which is higher than a tenfold increase, thanks to notable development in cataract surgeries and high per-client transactions.
International brands have long monopolized the intraocular lens market in India expanding at a CAGR of 11%, particularly the high-end ones, putting patients at a financial disadvantage due to the exorbitant prices of imported devices.
Increasing Influx of Medical Tourists is Likely to Boost the Adoption of PIOL Procedure
Demand in Germany is set to increase at a value of 2.7% in Europe with a value share of 34.1% of the phakic intraocular lenses (IOL) market during the forecast period. The country has high volumes of myopic population groups, with around 50% progression of myopic maculopathy, as per a cohort study by the Gutenberg Health Study (GHS), in 2022.
Indications associated with macular degeneration and the increasing diabetic population within the country, propose a need for corrective procedural uptake considering the United Kingdom to expand at a CAGR of 9.40%. These factors are anticipated to spur demand for phakic intraocular lenses in Germany over the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Adoption of Posterior Chamber Phakic IOL to Remain High
Sales of posterior chamber phakic IOL are expected to increase at a value share of 68% during the assessment period. Posterior chamber phakic intraocular lens implantation is a procedure for implanting an intraocular lens in front of the native crystalline lens. The advantages of posterior chamber phakic IOL implantation include potential reversibility, accommodation preservation, and minimal complications.
Demand for Phakic Intraocular Lenses for Myopia is Likely to Gain Traction
Demand in the myopia segment is anticipated to hold a market share of 36% during the forecast period. Ocular diseases have observed high variations in terms of disease prevalence, and indications like myopia have presented a high rate of prevalence worldwide. The growing need to address ocular disease progressions, along with the rising development of implantable devices will propel sales in this segment.
Sales of Phakic Intraocular Lenses across Hospitals might Continue to rise
Hospitals held the high market share at 55.0%. Insertion of an intraocular lens implant is the most common eye surgery procedure. Around 6 million procedures are done annually by eye surgeons as it requires huge capital investment for surgical and theatre equipment, hospitals present a great value in terms of procedural adoption rates.
Some of the prominent players profiled in the global market are-
Some of the important developments of the key players in the market are:
| Attribute | Details |
|---|---|
| Growth Rate | CAGR of 8.1% from 2023 to 2033 |
| Market value in 2023 | US$ 412.9 million |
| Market value in 2033 | US$ 897.4 million |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | US$ million for Value and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customisation Scope | Available on Request |
The market is valued at US$ 412.9 million in 2023.
Olympus, Verathon Inc, and Duomed are the key market players.
The market is forecast to register a CAGR of 8.1% through 2033.
The market is expected to reach US$ 897.4 million by 2033.
Sales in China are expected to increase at an 11.80% CAGR over the forecast period.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Supply Chain Analysis
3.5.1. Supply Side Participants and their Roles
3.5.1.1. Producers
3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers)
3.5.1.3. Wholesalers and Distributors
3.5.2. Value Added and Value Created at Node in the Supply Chain
3.5.3. List of Raw Material Suppliers
3.5.4. List of Existing and Potential Buyer’s
3.6. Investment Feasibility Matrix
3.7. Value Chain Analysis
3.7.1. Profit Margin Analysis
3.7.2. Wholesalers and Distributors
3.7.3. Retailers
3.8. PESTLE and Porter’s Analysis
3.9. Regulatory Landscape
3.9.1. By Key Regions
3.9.2. By Key Countries
3.10. Regional Parent Market Outlook
3.11. Production and Consumption Statistics
3.12. Import and Export Statistics
4. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) & Volume (Units) Analysis, 2017 to 2022
4.2. Current and Future Market Size Value (US$ Million) & Volume (Units) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Product
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Product, 2017 to 2022
5.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Product, 2023 to 2033
5.3.1. Posterior Chamber Phakic IOL
5.3.2. Anterior Chamber Phakic IOL
5.4. Y-o-Y Growth Trend Analysis By Product, 2017 to 2022
5.5. Absolute $ Opportunity Analysis By Product, 2023 to 2033
6. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Indication
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Indication, 2017 to 2022
6.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Indication, 2023 to 2033
6.3.1. Myopia
6.3.2. Hyperopia
6.3.3. Astigmatism
6.4. Y-o-Y Growth Trend Analysis By Indication, 2017 to 2022
6.5. Absolute $ Opportunity Analysis By Indication, 2023 to 2033
7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By End User, 2017 to 2022
7.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By End User, 2023 to 2033
7.3.1. Hospitals
7.3.2. Ophthalmology Clinics
7.3.3. Ambulatory Surgical Centers
7.4. Y-o-Y Growth Trend Analysis By End User, 2017 to 2022
7.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Region, 2017 to 2022
8.3. Current Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Western Europe
8.3.4. Eastern Europe
8.3.5. South Asia and Pacific
8.3.6. East Asia
8.3.7. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2022
9.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. The USA
9.2.1.2. Canada
9.2.2. By Product
9.2.3. By Indication
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Product
9.3.3. By Indication
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2022
10.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Product
10.2.3. By Indication
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Product
10.3.3. By Indication
10.3.4. By End User
10.4. Key Takeaways
11. Western Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2022
11.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Western Europe
11.2.2. By Product
11.2.3. By Indication
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Product
11.3.3. By Indication
11.3.4. By End User
11.4. Key Takeaways
12. Eastern Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2022
12.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Poland
12.2.1.2. Russia
12.2.1.3. Czech Republic
12.2.1.4. Romania
12.2.1.5. Rest of Eastern Europe
12.2.2. By Product
12.2.3. By Indication
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Product
12.3.3. By Indication
12.3.4. By End User
12.4. Key Takeaways
13. South Asia and Pacific Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2022
13.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Bangladesh
13.2.1.3. Australia
13.2.1.4. New Zealand
13.2.1.5. Rest of South Asia and Pacific
13.2.2. By Product
13.2.3. By Indication
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Product
13.3.3. By Indication
13.3.4. By End User
13.4. Key Takeaways
14. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2022
14.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Product
14.2.3. By Indication
14.2.4. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Product
14.3.3. By Indication
14.3.4. By End User
14.4. Key Takeaways
15. Middle East and Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2022
15.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Product
15.2.3. By Indication
15.2.4. By End User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Product
15.3.3. By Indication
15.3.4. By End User
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Product
16.1.2.2. By Indication
16.1.2.3. By End User
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Product
16.2.2.2. By Indication
16.2.2.3. By End User
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Product
16.3.2.2. By Indication
16.3.2.3. By End User
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Product
16.4.2.2. By Indication
16.4.2.3. By End User
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Product
16.5.2.2. By Indication
16.5.2.3. By End User
16.6. United Kingdom
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Product
16.6.2.2. By Indication
16.6.2.3. By End User
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Product
16.7.2.2. By Indication
16.7.2.3. By End User
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Product
16.8.2.2. By Indication
16.8.2.3. By End User
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Product
16.9.2.2. By Indication
16.9.2.3. By End User
16.10. Poland
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Product
16.10.2.2. By Indication
16.10.2.3. By End User
16.11. Russia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Product
16.11.2.2. By Indication
16.11.2.3. By End User
16.12. Czech Republic
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Product
16.12.2.2. By Indication
16.12.2.3. By End User
16.13. Romania
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Product
16.13.2.2. By Indication
16.13.2.3. By End User
16.14. India
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Product
16.14.2.2. By Indication
16.14.2.3. By End User
16.15. Bangladesh
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Product
16.15.2.2. By Indication
16.15.2.3. By End User
16.16. Australia
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Product
16.16.2.2. By Indication
16.16.2.3. By End User
16.17. New Zealand
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Product
16.17.2.2. By Indication
16.17.2.3. By End User
16.18. China
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Product
16.18.2.2. By Indication
16.18.2.3. By End User
16.19. Japan
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Product
16.19.2.2. By Indication
16.19.2.3. By End User
16.20. South Korea
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Product
16.20.2.2. By Indication
16.20.2.3. By End User
16.21. GCC Countries
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Product
16.21.2.2. By Indication
16.21.2.3. By End User
16.22. South Africa
16.22.1. Pricing Analysis
16.22.2. Market Share Analysis, 2022
16.22.2.1. By Product
16.22.2.2. By Indication
16.22.2.3. By End User
16.23. Israel
16.23.1. Pricing Analysis
16.23.2. Market Share Analysis, 2022
16.23.2.1. By Product
16.23.2.2. By Indication
16.23.2.3. By End User
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Product
17.3.3. By Indication
17.3.4. By End User
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. STAAR SURGICAL
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.1.5.2. Product Strategy
18.1.1.5.3. Channel Strategy
18.1.2. Care Group
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.2.5.2. Product Strategy
18.1.2.5.3. Channel Strategy
18.1.3. Ophtec BV/Abbott
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.3.5.2. Product Strategy
18.1.3.5.3. Channel Strategy
18.1.4. Johnson & Johnson
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.4.5.2. Product Strategy
18.1.4.5.3. Channel Strategy
18.1.5. Ambu
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.5.5.2. Product Strategy
18.1.5.5.3. Channel Strategy
18.1.6. Boston Scientific
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.6.5.2. Product Strategy
18.1.6.5.3. Channel Strategy
18.1.7. Olympus
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.7.5.2. Product Strategy
18.1.7.5.3. Channel Strategy
18.1.8. Verathon Inc
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.8.5.2. Product Strategy
18.1.8.5.3. Channel Strategy
18.1.9. Duomed
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.9.5.2. Product Strategy
18.1.9.5.3. Channel Strategy
18.1.10. PENTAX Medical
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
18.1.10.5.2. Product Strategy
18.1.10.5.3. Channel Strategy
18.1.11. Neoscope Inc
18.1.11.1. Overview
18.1.11.2. Product Portfolio
18.1.11.3. Profitability by Market Segments
18.1.11.4. Sales Footprint
18.1.11.5. Strategy Overview
18.1.11.5.1. Marketing Strategy
18.1.11.5.2. Product Strategy
18.1.11.5.3. Channel Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Phakic Intraocular Lenses (IOL) Market
